Latest Bevacizumab Stories
Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
The supplement is intended to provide an overview of available knowledge regarding the use of NovoTTF Therapy for the treatment of recurrent glioblastoma, as well as its development for the treatment
HEIDELBERG, Germany, Oct.
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
In-demand research report “Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM”
Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals
-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept.
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.